

20th May 2022

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001 Scrip Code: BSE – AJANTPHARM 532331	National Stock Exchange of India Exchange Plaza, 5 th Floor, Plot No. C/1, G block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: NSE AJANTPHARM EQ
---	---

**Subject: - Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI
(Listing Obligations and Disclosure Requirements), 2015**

Dear Sir / Madam,

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of Related Party Transactions on a consolidated basis for the half year ended 31st March 2022.

Kindly take the same on your records.

Thanking you,

Yours faithfully,

Gaurang Shah
VP – Legal & Company Secretary

Encl.: a/a

Ajanta Pharma Limited

Disclosure of Related Party Transaction for the half year ended 31st March 2022

Rs in Crore

										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.								
S. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction (see Note 5 of the Circular)	Value of the related party transaction as approved by the audit committee (see Note 6a of the Circular)	Value of transaction during the reporting period (see Note 6b)	In case monies are due to either party as a result of the transaction (see Note 1)		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening Balance	Closing Balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost (see Note 7 of the Circular)	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
61	Ajanta Pharma Limited		Seth Bhagwandas Agarwal Charitable Trust		Promoter group is able to exercise significant control over this entity	Donation expense	0.35	0.15	-	-								
62	Ajanta Pharma Limited		Tanya Agrawal		Daughter of Managing Director	Short Term Employee benefits	-	0.04	-	-								
63	Ajanta Pharma Limited		Tanya Agrawal		Daughter of Managing Director	Post-employment benefits	-	0.00	-	-								
64	Ajanta Pharma Limited		Yogesh M. Agrawal		Managing Director & KMP	Short Term Employee benefits	-	5.53	-	-								
65	Ajanta Pharma Limited		Yogesh M. Agrawal		Managing Director & KMP	Post-employment benefits	-	0.04	-	-								
66	Ajanta Pharma Limited		Yogesh M. Agrawal		Managing Director & KMP	Commission to Directors	-	3.61	-	-								
67	Ajanta Pharma Limited		Yogesh M. Agrawal		Managing Director & KMP	Commission payable	-		1.64	5.25								
68	Ajanta Pharma Limited		Yogesh M. Agrawal, trustee Yogesh Agrawal Trust		Promoter	Dividend paid	-	11.91	-	-								
69	Ajanta Pharma Limited		Yogesh M. Agrawal, Trustee Yogesh Agrawal Trust		Promoter	Buyback of Equity Shares	-	39.04	-	-								

Note: Amount approved by Audit Committee is for the entire financial year